Despite their success, immune checkpoint blockers (ICB) benefit only a subset of patients and pose potential risk of serious immune-related adverse events, underscoring the critical need for new strat
Many cancers recruit monocytes/macrophages and polarize them into tumor-associated macrophages (TAMs). TAMs promote tumor growth and metastasis and inhibit cytotoxic T cells, preventing immune control
Diverse combination therapies are being investigated to overcome the limitations of immune checkpoint inhibitors. However, determining the optimal combination therapy remains a challenge. Herein, we d
